Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

106.54 +4.40 (+4.31%)
Streaming Delayed Price Updated: 1:15 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 403,654
Open 102.38
Bid (Size) 106.15 (7)
Ask (Size) 106.65 (7)
Prev. Close 102.14
Today's Range 101.26 - 107.03
52wk Range 76.53 - 131.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga

Performance

YTD
-5.17%
-5.17%
1 Month
-4.52%
-4.52%
3 Month
+19.72%
+19.72%
6 Month
+4.14%
+4.14%
1 Year
+9.65%
+9.65%

More News

Read More
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Via Benzinga
Exposures Product Safety
The Analyst Landscape: 17 Takes On BioNTech
Via Benzinga
What Analysts Are Saying About BioNTech Stock
Via Benzinga
Breaking Down BioNTech: 16 Analysts Share Their Views
Via Benzinga
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
Via Investor's Business Daily
Topics Government
Exposures Political
BioNTech Stock Got A IBD RS Rating Lift
Via Investor's Business Daily
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
Via Benzinga
BioNTech to Acquire Biotheus to Boost Oncology Strategy
From BioNTech SE
Via GlobeNewswire
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Via Benzinga
This Bank of America Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Via Benzinga
Topics Government
Exposures Political
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
Via Benzinga
Exposures COVID-19
BioNTech Jumps On Surprise Profit, Wide Sales Beat; But Lowers Outlook
Via Investor's Business Daily
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
BioNTech to Host Innovation Series R&D Day on November 14, 2024
From BioNTech SE
Via GlobeNewswire
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
Via The Motley Fool
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment
Via Benzinga
Exposures Product Safety
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
From BioNTech SE
Via GlobeNewswire
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.